Kairos Pharma (KAPA)
Develops resistance-focused cancer therapies led by ENV-105.
Something off on this page? Send us feedback.
Develops oncology therapies designed to counter treatment resistance and immune suppression, led by ENV-105 in prostate cancer and EGFR-mutated lung cancer. It is a virtual, pre-revenue clinical-stage company whose development work depends on academic sites, third-party providers and licensed Cedars-Sinai intellectual property.
Develops cancer therapies intended to address drug resistance and immune suppression, with ENV-105, a CD105-targeting antibody, as the clinical lead. The program is being tested alongside androgen-receptor signaling inhibitors in prostate cancer and osimertinib in EGFR-mutated lung cancer. Earlier programs include activated T cells for glioblastoma and small molecules and biologics spanning immune modulation, tumor biology and cachexia.
Operates as a virtual, clinical-stage biopharmaceutical company with no approved products or product-sales revenue. Its work is centered in the United States and carried out through academic trial sites, contract providers and third-party manufacturers. Prospective revenue depends on clinical development, regulatory approval and product sales, partnerships, sublicensing or other strategic arrangements; much of the portfolio is covered by exclusive Cedars-Sinai license agreements.
Company facts
No analyst consensus on record.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $2.6M · Total debt $0 · Total assets $4.5M · Shareholders' equity $4.2M
- Revenue
- $0
- Operating income
- −$1.4M
- Net income
- −$1.4M
No dividends on record.
| Institutions11 holders · as of Mar 31, 2026 | 2.54% | 85.9K shares | |
| Otherremainder | 97.46% | 3.30M shares |
3.39M company shares as of Sep 3, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
Two share counts disagree (3.39M in the company's Sep 3, 2026 report, 3.06M elsewhere); stakes use the report.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
Vanguard Capital Management LLCInstitution | 0.98% | 231,878 | 13Fas of Mar 31, 2026 |
Geode Capital Management, LLCInstitution | 0.47% | 111,290 | 13Fas of Mar 31, 2026 |
Vanguard Fiduciary Trust CoInstitution | 0.27% | 63,884 | 13Fas of Mar 31, 2026 |
Aptus Capital Advisors, LLCInstitution | 0.19% | 44,286 | 13Fas of Mar 31, 2026 |
Sevenbridge Financial Group, LLCInstitution | 0.19% | 44,286 | 13Fas of Mar 31, 2026 |
| See all 11 → | |||
13F — a manager's quarterly holdings
Insider tradesForm 4
Nothing filed in the last 12 months.
- Johnson & Johnson
Androgen-receptor therapies contest resistant-prostate treatment pathways.
- Pfizer
XTANDI contests androgen-receptor treatment in resistant prostate cancer.
- Sanofi (ADR)
JEVTANA is a later-line alternative in resistant prostate cancer.
- Novartis (ADR)
PLUVICTO and TABRECTA overlap in prostate and MET-positive lung cancer.
ComparePre-market
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Kairos Pharma | $1.69 | +4.97% | $4.8M | — | — | — | — |
| Johnson & Johnson | $275.21 | −0.01% | $663.23B | 31.9 | 23.1 | 6.8 | +6.6% |
| Pfizer | $28.99 | −0.14% | $165.40B | 38.3 | 10.4 | 2.6 | +2.6% |
| Sanofi (ADR) | $44.57 | +0.24% | $106.78B | 78.2 | — | 1.9 | +11.2% |
| Novartis (ADR) | $162.04 | −0.25% | $308.79B | 24.5 | 17.3 | 5.6 | +0.9% |
| Median | 35.1 | 17.3 | 4.1 | +4.6% |